Recombinant Modification methylase XamI (xamIM), partial

Shipped with Ice Packs
In Stock

Description

Introduction

Recombinant Modification Methylase XamIM (partial) refers to a bioengineered enzyme derived from the XmaI restriction-modification (R-M) system of Xanthomonas malvacaerum. This system comprises a restriction endonuclease (XmaI) and a DNA methyltransferase (XamIM), which together provide immunity against foreign DNA by modifying host DNA and cleaving unmethylated invaders. The methylase, encoded by the xamIM gene, methylates adenine residues within the recognition sequence 5'-CCCGGG-3', rendering DNA resistant to XmaI restriction activity .

Key Features

  • Recognition Sequence: 5'-CCCGGG-3' (palindromic, 6 bp).

  • Methylation Site: Adenine at the third position (5'-CCCGGGG-3').

  • Enzyme Class: Type II R-M system, where methyltransferase and endonuclease act independently .

Structure and Function

The XamIM methyltransferase operates as a monomer, methylating one strand of duplex DNA at a time . Its structure includes a catalytic domain homologous to other Type II methyltransferases, with conserved motifs for S-adenosylmethionine (SAM) binding and sequence recognition .

Table 2: Cloning Vectors and Hosts

Vector/HostRoleReference
pKL19-2Cloning vector with XmaI/SmaI site
E. coli RR1Host for plasmid library
E. coli K802Host for XmaI restriction assay

Applications

Recombinant XamIM has been utilized in:

  • Synthetic Biology: Site-selective inhibition of Type IIS restriction enzymes (e.g., BsaI, LguI) by methylating overlapping recognition sites .

  • DNA Assembly: Protection of engineered plasmids during restriction-based cloning .

  • Epigenetic Studies: Modulation of DNA methylation patterns for gene regulation .

Table 3: Applications of XamIM

ApplicationDescriptionReference
Restriction InhibitionBlocks Type IIS endonucleases by methylating DNA
Plasmid EngineeringProtects plasmids from XmaI digestion during cloning
Epigenetics ResearchTool for studying DNA methylation-dependent gene regulation

Research Findings

  • Enzymatic Efficiency: XamIM exhibits high methylation activity, with >90% protection of plasmids from XmaI digestion .

  • Sequence Engineering: Rational design of XamIM variants targeting altered motifs (e.g., 5'-CCCGGT) has been demonstrated .

  • Thermostability: Recombinant XamIM retains activity at 37°C, suitable for in vitro applications .

Product Specs

Form
Lyophilized powder. We will ship the available format, but if you have specific format requirements, please note them when ordering, and we will fulfill your request.
Lead Time
Delivery times vary based on purchasing method and location. Please consult your local distributor for specific delivery times. All proteins are shipped with standard blue ice packs. For dry ice shipping, please contact us in advance, as additional charges apply.
Notes
Avoid repeated freezing and thawing. Working aliquots can be stored at 4°C for up to one week.
Reconstitution
Briefly centrifuge the vial before opening to collect contents at the bottom. Reconstitute the protein in sterile deionized water to a concentration of 0.1-1.0 mg/mL. We recommend adding 5-50% glycerol (final concentration) and aliquoting for long-term storage at -20°C/-80°C. Our default final glycerol concentration is 50% for your reference.
Shelf Life
Shelf life depends on several factors: storage conditions, buffer components, storage temperature, and protein stability. Generally, the liquid form has a shelf life of 6 months at -20°C/-80°C, while the lyophilized form has a shelf life of 12 months at -20°C/-80°C.
Storage Condition
Store at -20°C/-80°C upon arrival. Aliquot for multiple uses. Avoid repeated freeze-thaw cycles.
Tag Info
The tag type will be determined during the manufacturing process. If you have a specific tag type requirement, please inform us, and we will prioritize developing the specified tag.
Synonyms
xamIM; Modification methylase XamI; M.XamI; EC 2.1.1.72; Adenine-specific methyltransferase XamI
Buffer Before Lyophilization
Tris/PBS-based buffer, 6% Trehalose.
Datasheet
Please contact us to get it.
Protein Length
Partial
Purity
>85% (SDS-PAGE)
Species
Xanthomonas campestris pv. amaranthicola
Target Names
xamIM
Uniprot No.

Target Background

Function
This methylase recognizes the double-stranded DNA sequence GTCGAC, methylates the adenine at the 5' position on both strands, and protects the DNA from cleavage by the XamI endonuclease.
Protein Families
N(4)/N(6)-methyltransferase family

Q&A

What are DNA modification methylases and how do they function in restriction-modification systems?

Modification methylases are enzymes that catalyze the addition of methyl groups to specific nucleotides within DNA sequences. In restriction-modification (R-M) systems, methylases work in concert with restriction endonucleases to protect host DNA while restricting foreign DNA. The methylation activity targets specific DNA sequences, creating either N6-methyladenine (6mA), N5-methyl-cytosine (5mC), or N4-methylcytosine (4mC) modifications . These methylation patterns protect the host DNA from being cleaved by the corresponding restriction enzymes that recognize the same sequence pattern. For example, the M.SinI methylase specifically methylates the internal deoxycytidylate residue in the nucleotide sequence GG(A/T)CC, which prevents cleavage by restriction endonucleases R.SinI or R.AvaII that target this same sequence .

What distinguishes Type I restriction-modification systems from other R-M systems?

Type I R-M systems are distinct in that they operate as protein complexes with both methylation and restriction endonuclease activities targeting double-stranded DNA at bipartite motifs separated by nonspecific spacers. These systems consist of three essential subunit components: HsdM (responsible for modification), HsdS (defining specificity), and HsdR (mediating restriction) . The specificity subunit (HsdS) is required for both modification and restriction activities and contains two variable target recognition domains (TRDs) that are typically 450-500 bp in length and separated by a central conserved region . Unlike other R-M systems, Type I systems can rapidly evolve to target new genomic sites through recombination-driven exchange of TRDs while maintaining self-protection. Additionally, these systems can undergo phase variation through multiple mechanisms including the exchange of position or recombination of multiple HsdS subunits, or variation in simple sequence repeat (SSR) tract lengths within HsdS or HsdM components .

How can recombinant methylases be expressed and purified for research applications?

Recombinant methylases can be produced by cloning methyltransferase genes into suitable expression vectors and transforming these constructs into expression hosts like Escherichia coli. As demonstrated with M.SinI methylase, researchers can isolate and purify the enzyme from E. coli harboring a recombinant plasmid containing the methylase gene (such as the Salmonella infantis DNA insert in plasmid pSI4) . The purification process typically involves:

  • Cell lysis under optimized conditions to preserve enzyme activity

  • Initial fractionation using ammonium sulfate precipitation

  • Sequential chromatography steps:

    • Ion exchange chromatography (DEAE-cellulose or similar)

    • Affinity chromatography (heparin or DNA-affinity columns)

    • Size exclusion chromatography for final polishing

For recombinant methylases with affinity tags, immobilized metal affinity chromatography (IMAC) may be employed. The purification protocol must be optimized to maintain enzymatic activity while achieving high purity, and activity assays should be performed at each purification stage to track enzyme recovery.

What methodologies are most effective for verifying methylation activity of recombinant methylases?

Several complementary approaches can be used to verify methylation activity:

  • Restriction Protection Assays:

    • Treat DNA with the recombinant methylase

    • Challenge the treated DNA with restriction enzymes sensitive to methylation

    • Analyze protection patterns via gel electrophoresis

    • For example, M.SinI methylation protects DNA against cleavage by R.SinI, R.AvaII, and partially against R.Sau96I

  • Radioisotope Incorporation:

    • Measure incorporation of radiolabeled methyl groups (e.g., from [³H]methyl-S-adenosylmethionine) into DNA

    • This approach has been used to quantify DNA methylation levels in cells treated with recombinant methioninase

  • Bisulfite Sequencing:

    • Convert unmethylated cytosines to uracil while leaving methylated cytosines unchanged

    • PCR amplification and sequencing reveal methylation patterns

    • Particularly useful for site-specific analysis

  • Methylation-Sensitive PCR:

    • Use of primers designed to amplify specific regions only when methylated or unmethylated

    • Methylation-sensitive arbitrarily-primed PCR has been used to evaluate DNA hypomethylation effects

  • Modern Sequencing-Based Methods:

    • SMRT (Single Molecule Real-Time) sequencing to directly detect methylated bases

    • Nanopore sequencing which can distinguish modified bases during sequencing

How can targeted DNA methylation be achieved using engineered recombinant methylases?

Targeted DNA methylation can be achieved by fusing DNA-binding domains with methyltransferase domains. A notable approach involves fusing catalytically inactive Cas9 (dCas9) with engineered prokaryotic DNA methyltransferases like MQ1 . This fusion creates a programmable DNA methylation system where:

  • The dCas9 component provides sequence-specific targeting guided by designed sgRNAs

  • The methyltransferase component (e.g., MQ1) performs the catalytic function of methylating DNA at the targeted locus

This approach enables:

  • Locus-specific cytosine modifications without impacting global methylation patterns

  • Rapid and efficient targeted DNA methylation within 24 hours

  • Potential applications in developmental biology, as demonstrated through CpG methylation induction in mice by zygote microinjection

When designing such systems, researchers must carefully consider:

  • The spacer region between dCas9 and the methyltransferase to ensure proper positioning of the methyltransferase domain

  • Optimization of sgRNA design to minimize off-target effects

  • Verification of methylation specificity through whole-genome bisulfite sequencing or similar approaches

What controls are essential when evaluating the efficiency of recombinant methylase activity?

To rigorously evaluate recombinant methylase activity, the following controls are critical:

  • Negative Controls:

    • Untreated DNA samples to establish baseline methylation levels

    • Heat-inactivated enzyme preparations to control for contaminating activities

    • Reaction mixtures lacking S-adenosylmethionine (SAM) cofactor

  • Positive Controls:

    • Commercial methyltransferases with known activity on the same sequences

    • Well-characterized methylation standards for calibration

    • Known methylated DNA samples for comparison

  • Specificity Controls:

    • DNA substrates lacking the recognition sequence

    • DNA substrates with mutated recognition sequences

    • Competitor DNA to test selectivity

  • Quantitative Standards:

    • Concentration gradients of substrate DNA

    • Time-course experiments to determine reaction kinetics

    • Titration of enzyme concentrations

  • Comparative Controls:

    • Comparison with established methylation agents (e.g., 5-azacytidine) when studying DNA hypomethylation effects

    • Parallel testing of wild-type and engineered variants of the methylase

How do the functional domains of methylases contribute to sequence specificity and catalytic activity?

Methylase functional domains have distinct roles in ensuring proper substrate recognition and catalytic activity:

DomainFunctionStructural FeaturesEffect of Mutations
Target Recognition Domains (TRDs)Define DNA sequence specificityVariable regions ~450-500 bp in lengthAlter recognition sequence specificity
Catalytic DomainPerforms methyl transferConserved motifs (I-X)May reduce/eliminate catalytic activity
S-adenosylmethionine (SAM) Binding DomainCofactor bindingGlycine-rich regionsReduces methylation efficiency
DNA Binding InterfacePositions target DNABasic amino acid clustersDecreases DNA affinity

In Type I R-M systems, the specificity subunit (HsdS) contains two variable TRDs separated by a central conserved region (CCR) . The sequence specificity is determined by these TRDs, and recombination-driven exchange of TRDs allows these systems to evolve to target new genomic sites while avoiding restriction of the host chromosome . The modification subunit (HsdM) contains the catalytic domain responsible for the methyl transfer reaction.

Understanding these domain relationships is crucial when engineering recombinant methylases with novel specificities or when troubleshooting issues with catalytic efficiency.

What approaches can be used to modify the sequence specificity of recombinant methylases?

Several approaches have been developed to modify sequence specificity of recombinant methylases:

  • TRD Domain Swapping:

    • Exchange Target Recognition Domains between different methylases

    • This mimics natural recombination observed in Type I R-M systems

    • Particularly effective with Type I systems where TRDs are well-defined structural units

  • Directed Evolution:

    • Random mutagenesis of TRD regions followed by selection for desired specificity

    • Phage-displayed libraries of methylase variants

    • Selection using methylation-dependent restriction protection

  • Rational Design:

    • Structure-guided mutagenesis of amino acids in the DNA-binding interface

    • Computational modeling to predict specificity-altering mutations

    • Introduction of specific amino acid changes that alter hydrogen bonding with DNA bases

  • Fusion with Programmable DNA-Binding Domains:

    • Creation of fusion proteins with dCas9 or similar DNA-binding domains

    • The DNA-binding domain provides specificity while the methylase domain provides catalytic activity

    • This approach has been successful in achieving targeted DNA methylation in vivo

  • Chimeric Methylases:

    • Construction of hybrid enzymes combining domains from different methylases

    • Particularly useful when combining well-characterized domains with known properties

Each approach has distinct advantages depending on research goals and the specific methylase being modified.

How can researchers troubleshoot inconsistent methylation patterns in recombinant methylase experiments?

When facing inconsistent methylation patterns, researchers should systematically investigate:

  • Enzyme Activity Issues:

    • Verify enzyme stability during storage and reaction conditions

    • Confirm SAM cofactor quality and concentration

    • Examine potential inhibitors in the reaction mixture

    • Test enzyme activity with control substrates

  • Substrate Accessibility Problems:

    • Check DNA purity and secondary structure formation

    • Ensure optimal reaction conditions (temperature, ionic strength)

    • Consider DNA topology (supercoiled vs. linear)

    • Evaluate whether competing DNA-binding proteins are present

  • Sequence Context Effects:

    • Analyze flanking sequences around target sites

    • Test methylation efficiency on isolated fragments vs. complex templates

    • Consider potential effects of pre-existing methylation patterns

  • Experimental Design Factors:

    • Review incubation time and enzyme:substrate ratios

    • Ensure proper pH and buffer composition

    • Verify that stopping conditions do not interfere with downstream analysis

  • Detection Method Limitations:

    • Use complementary detection techniques (restriction protection and direct methylation detection)

    • Consider sensitivity limits of the analytical methods

    • Implement appropriate controls for each detection method

A methodical approach to these factors, combined with careful documentation of experimental conditions, can help identify the source of inconsistencies.

How can statistical approaches help analyze methylation data from recombinant methylase experiments?

Statistical analysis of methylation data requires specialized approaches:

  • Quantitative Analysis of Methylation Efficiency:

    • Calculate percentage of protected sites (restriction protection assays)

    • Determine methylation densities across target regions

    • Apply regression models to analyze treatment effects across multiple experiments

  • Spatial Pattern Analysis:

    • Evaluate clustering of methylation events

    • Apply spatial statistics to identify methylation hotspots

    • Use autocorrelation analyses to detect systematic patterns

  • Experimental Design Considerations:

    • Implement Analysis of Variance (ANOVA) to evaluate significant effects

    • Apply central composite design (CCD) for optimization experiments

    • Utilize response surface methodology (RSM) for multi-parameter optimization

  • Handling Heterogeneity:

    • Account for cluster heterogeneity in experimental designs

    • Consider both size heterogeneity and outcome distribution heterogeneity

    • Be aware that ignoring heterogeneity may result in underpowered experiments

  • Visual Representation Approaches:

    • Design tables with appropriate visual aids to improve readability

    • Consider color encoding or bar representations for complex data patterns

    • Implement appropriate table formatting (e.g., zebra striping) to facilitate complex comparisons

When analyzing methylation experiments, researchers should calculate both statistical significance and effect sizes to provide a complete picture of methylation impacts.

What role do recombinant methylases play in studying epigenetic regulation mechanisms?

Recombinant methylases serve as powerful tools for studying epigenetic regulation through:

  • Targeted Epigenetic Modifications:

    • Enable precise introduction of methylation marks at specific genomic loci

    • Allow study of cause-effect relationships between methylation and gene expression

    • Facilitate investigation of methylation in pluripotency loss and transcriptome governance during development

  • Disease Modeling:

    • Help recreate aberrant methylation patterns observed in diseases

    • Aid in studying methylation's role in tumorigenesis, aging, and neurodegenerative diseases

    • Enable modeling of epigenetic dysregulation without genetic alterations

  • Temporal Control of Methylation:

    • Allow induction of methylation at specific developmental timepoints

    • Enable study of methylation dynamics during cellular differentiation

    • Facilitate investigation of methylation reversibility and stability

  • Mechanistic Studies:

    • Help dissect the molecular machinery involved in reading methylation marks

    • Enable investigation of crosstalk between different epigenetic modifications

    • Support research into pioneer factors that can overcome methylation-mediated repression

Recombinant methylases like those fused with dCas9 provide a rapid and efficient strategy to achieve locus-specific methylation without impacting global patterns, offering unprecedented control for epigenetic studies .

How can recombinant methylases be used to study DNA methylation patterns in disease states?

Recombinant methylases offer several approaches to study disease-associated methylation patterns:

  • Modeling Aberrant Methylation:

    • Recreate disease-specific hypermethylation or hypomethylation patterns

    • Study functional consequences of disease-associated methylation changes

    • Test interventions aimed at normalizing methylation patterns

  • Methylation Restriction Approaches:

    • Use recombinant methioninase (rMETase) to restrict methionine and induce DNA hypomethylation

    • Compare rMETase-induced hypomethylation with that caused by DNA methyltransferase inhibitors like 5-azacytidine

    • Study differential sensitivity of disease and normal cells to methylation alterations

  • Functional Validation Studies:

    • Targeted methylation of candidate disease-associated loci

    • Reverse engineering of methylation patterns observed in patient samples

    • Assessment of phenotypic consequences of specific methylation changes

  • Therapeutic Development:

    • Screen for compounds that can modulate the activity of methylation machinery

    • Evaluate approaches for targeted demethylation of silenced tumor suppressor genes

    • Develop methylation-based biomarkers for disease detection and monitoring

These approaches leverage recombinant methylases to move beyond correlative observations toward mechanistic understanding of methylation's role in disease pathogenesis.

What are the latest innovations in recombinant methylase engineering for research applications?

Recent innovations in recombinant methylase engineering include:

  • Programmable Epigenome Editors:

    • Development of dCas9-methyltransferase fusions allowing RNA-guided targeted methylation

    • Creation of modular systems with swappable effector domains

    • Engineering of split methylase systems for improved specificity

  • Temporal Control Systems:

    • Light-inducible methyltransferase systems

    • Chemically-regulated methylase activity using small molecules

    • Integration with synthetic gene circuits for programmed methylation dynamics

  • Enhanced Specificity Approaches:

    • Rational engineering of TRDs to reduce off-target activity

    • Development of high-fidelity variants with reduced non-specific activity

    • Creation of bipartite systems requiring co-localization of split enzymes

  • Multi-functional Epigenetic Modifiers:

    • Combined systems that can simultaneously modify histones and DNA

    • Dual-function enzymes that both methylate DNA and recruit other epigenetic machinery

    • Integration with chromatin remodeling complexes for coordinated epigenome editing

  • Delivery Innovations:

    • Development of cell-permeable recombinant methylases

    • Targeted delivery systems for tissue-specific methylation modulation

    • In vivo applications using zygote microinjection for developmental studies

These innovations expand the research toolkit for precise epigenetic manipulation and open new avenues for understanding methylation biology.

How can contradictory methylation data be reconciled in complex experimental systems?

When facing contradictory methylation data, researchers should:

  • Evaluate Methodological Differences:

    • Compare detection methods (bisulfite sequencing, enzyme-based methods, antibody-based approaches)

    • Assess sensitivity and specificity of each method

    • Consider whether methods detect different forms of methylation (5mC vs. 5hmC)

  • Account for Cellular Heterogeneity:

    • Determine if contradictions arise from mixed cell populations

    • Consider single-cell approaches to resolve population heterogeneity

    • Evaluate clonal variation in methylation patterns

  • Examine Temporal Dynamics:

    • Assess whether contradictions reflect different timepoints in dynamic processes

    • Consider methylation turnover rates in the system

    • Implement time-course experiments to capture methylation dynamics

  • Analyze Environmental Influences:

    • Evaluate culture conditions that might affect methylation

    • Consider cell density, passage number, and media composition

    • Examine potential epigenetic memory effects from previous conditions

  • Implement Integrated Analysis:

    • Correlate methylation data with gene expression, chromatin accessibility, and histone modifications

    • Use multiple complementary approaches and triangulate findings

    • Apply statistical methods specifically designed for heterogeneous data

Through systematic investigation of these factors, researchers can often reconcile seemingly contradictory data and gain deeper insights into the complex regulation of DNA methylation.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.